Genprex

Investor

Downloads


Executive Summary

A one-page summary and overview of Genprex.

Download

Investor Presentation

Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.

Download

TUSC2 Bibliography

A bibliography of selected publications describing the TUSC2 gene.

Download

PDX1 and MAFA Bibliography

A bibliography of selected publications describing the PDX1 and MAFA genes.

Download

2020 International Journal of Molecular Sciences

The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.

Download

2019 AACR KRAS and LKB1 Poster – Meraz

The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.

Download

2019 Nature Research Scientific Reports

The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.

Download

2019 AACR Hu-PDX Poster – Meraz

The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.

Download

2017 AACR Poster – Meraz

The poster presents data that TUSC2 is synergistic with anti-PD1 in syngeneic mouse models of lung cancer.

Download

2012 AACR Poster – Yan

The poster describes a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanoparticle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.

Download

2012 AACR Poster – Meng

The poster presents data on the synergistic antitumor activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC.

Download

2011 AACR Poster – Lu

The poster presents data on systemic gene therapy with TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer.

Download

Private: 2011 AACR Abstract – Lu

We’re passionate about the work we’re doing to revolutionize the fight against cancer, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.

Download